Research bundles

15 000+ verified orders

Shred Bundle

Low stock

Pair retatrutide receptor research with the GHRH-analogue research of tesamorelin. Shred brings these distinct metabolic research directions together in a ready-made selection, with clear vial quantities, included BAC Water and a transparent saving against buying every component separately.
590,32 € 450,40 € Save 139,92 € (23.7%)

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

Shred Bundle

Original price was: 590,32 €.Current price is: 450,40 €.

Pair retatrutide receptor research with the GHRH-analogue research of tesamorelin. Shred brings these distinct metabolic research directions together in a ready-made selection, with clear vial quantities, included BAC Water and a transparent saving against buying every component separately.

SKU: ADRIA-PRIVATE-SHRED-BUNDLE

Every compound, clearly identified

Specifications

Tesamorelin · 20 mg

Molecular profile

Sequence
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular mass
5135.9 g/mol
CAS number
218949-48-5
Molecular formula
C221H366N72O67S

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
GHRH analogue research compound; supplied strictly for research use only.

Retatrutide · 20 mg

Molecular profile

Sequence
Y-Aib-QGTFTSDYSI-alphaMeLeu-LDKK(AEEA-gamma-Glu-C20 diacid)-AQAibAFIEYLLEGGPSSGAPPPS-NH2
Molecular mass
4731.4 g/mol
CAS number
2381089-83-2
Molecular formula
C221H342N46O68

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
GLP-3 research compound; supplied strictly for research use only.

Bacteriostatic Water · 10 ml

Molecular profile

Molecular mass
Water: 18.015 g/mol; benzyl alcohol: 108.14 g/mol.
CAS number
Water: 7732-18-5; benzyl alcohol: 100-51-6.
Molecular formula
Water: H2O; benzyl alcohol: C7H8O.

Material record

Physical appearance
Clear, colourless aqueous solution.
Solubility
Aqueous solution; miscible with water.
Product note
Aqueous laboratory solvent formulation containing 0.9% benzyl alcohol preservative with a pH range of 4.5–7.0; supplied strictly for research and laboratory use.

The research behind the combination

Metabolic research from two angles

Shred is organised around two different routes into metabolic and body-composition research. Retatrutide is investigated through GLP-1, GIP and glucagon receptors, while tesamorelin is a GHRH analogue studied in the growth-hormone axis. The rationale is complementary experimental coverage rather than simply adding more of the same type of material.

For study planning, this pairing brings receptor-mediated metabolic signalling and endocrine-related endpoints into the same research collection. Published work on the individual compounds helps explain why those questions may be considered alongside one another. It does not establish the performance of their combined use.

The bundle keeps the compounds, strengths and quantities visible and separately packaged. Included BAC Water and one clearly stated total make the selection easier to review, compare and order.

  • Two distinct metabolic research pathways
  • Individual compounds and strengths stay clear
  • Complete component value and saving shown

Explore the individual components

Tesamorelin · 20 mg

Description of Tesamorelin

Tesamorelin, a polypeptide consisting out of 44 amino acids of GHRH is specific for addition of trans-3-hexanoic acid to the peptide’s sequence, which makes the compound more stable in human plasma and also increases its half-life. Tesamorelin has been found effective in reducing visceral adiposity in patients with lipodystrophy, leading to its approval for clinical use in the United States in 2010. It was developed by Theratechnologies, Inc., and was not intended for weight loss or treatment of obesity but specifically targeted the reduction of excess abdominal fat associated with HIV medication-induced lipodystrophy. Its major effects are related to glucose and lipid metabolism, and it is being evaluated as a treatment of insulin resistance, nonalcoholic fatty liver, peripheral nerve regeneration or cardiovascular diseases. Lets have a look at several research results in the field of tesamorelin effects.

[1]

Research Confirmed Effects

Tesamorelin, a synthetic analog of growth hormone-releasing factor, addresses excess visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, a condition characterized by body composition changes, including lipohypertrophy. Lipodystrophy adversely impacts patients' quality of life and is often linked to antiretroviral therapy (ART), particularly protease inhibitors. Tesamorelin's efficacy in reducing VAT has been demonstrated through randomized Phase 3 trials, showing significant reductions in VAT levels over six months of treatment. Notably, patient characteristics such as metabolic syndrome, elevated triglyceride levels, and white race are associated with a higher likelihood of VAT reduction with tesamorelin therapy.

Tesamorelin's approval in 2010 marked a significant advancement in the treatment of HIV-associated lipodystrophy, offering a targeted therapeutic approach to reduce excess adiposity in affected patients. Prior to its availability, treatment options for lipodystrophy were limited, often relying on lifestyle modifications and surgical interventions with varying degrees of success. Tesamorelin's effectiveness in reducing VAT by nearly 20% surpasses that of other available therapies, positioning it as a valuable intervention in managing lipodystrophy-related complications in HIV-infected patients. Thus, tesamorelin is 4 times more effective in reducing adipocity.

[2], [3]

HIV patients are also at increased risk of developing cardiovascular disease (CVD), mostly due to abnormal fat deposition, and also due to antiretroviral drugs. Tesamorelin demonstrates efficacy in reducing visceral adipose tissue (VAT) and improving metabolic parameters in HIV-infected patients with treatment-associated central fat accumulation. In a 26-week randomized trial involving 412 patients, daily subcutaneous injections of tesamorelin resulted in a significant reduction in VAT by 15.2% compared to a 5.0% increase in the placebo group. Moreover, tesamorelin treatment led to improvements in triglyceride levels, total cholesterol to HDL cholesterol ratio, and insulin-like growth factor I (IGF-I) levels. These metabolic benefits, including reduced VAT and improved lipid profiles, suggest a potential therapeutic role for tesamorelin in managing central fat accumulation in HIV-infected individuals.

Furthermore, responders to tesamorelin therapy, defined as those achieving ≥8% reduction in VAT, experienced greater reductions in triglyceride levels and improvements in glucose homeostasis compared to nonresponders over a 52-week treatment period. Notably, tesamorelin's effects on metabolic parameters are associated with the percentage change in VAT, indicating a direct correlation between VAT reduction and metabolic improvements. These findings underscore the potential of tesamorelin to not only reduce visceral adiposity but also mitigate cardiovascular risk factors in HIV-infected patients, offering a promising therapeutic strategy beyond conventional interventions like statins.

[4], [5]

Highly active antiretroviral therapy (HAART) is linked with various endocrine and metabolic complications, including altered pituitary growth hormone (GH) secretion in human immunodeficiency virus (HIV) infection, with about one-third of patients exhibiting biochemical GH deficiency (GHD). Patients with HIV often experience reduced spontaneous GH secretion and GH response to stimuli, particularly those with HIV-related lipodystrophy, potentially due to factors like fat accumulation. Although the exact mechanisms underlying GHD in HIV patients are complex and not fully understood, tesamorelin, as a GH releasing hormone analogue, shows promise in reducing visceral fat in HIV-infected individuals with lipodystrophy, offering a safer alternative to high-dose recombinant human growth hormone with fewer side effects.

[6]

Peripheral nerve injuries lead to motor and sensory deficits with limited therapeutic options available. Growth hormone (GH)-based therapies offer promise in accelerating axonal regeneration and limiting atrophy of denervated muscle and Schwann cells (SCs) before reinnervation, potentially improving outcomes post-surgery. GH-based treatments act on multiple tissues involved in nerve regeneration, offering multi-modal mechanisms and potential secondary benefits for bone, tendon, and wound healing. FDA-approved drugs augmenting the GH axis facilitate potential clinical translation for peripheral nerve injury treatment. Research suggests GH manipulation, like tesamorelin, may improve outcomes, offering potential FDA-approved interventions for this challenging condition.

[7]

The study conducted at the University of Washington School of Medicine involved thirty adults, including those with mild cognitive impairment (MCI), who self-administered daily subcutaneous injections of tesamorelin or placebo for 20 weeks. Brain magnetic resonance imaging and spectroscopy protocols, cognitive testing, and blood sampling were conducted at baseline and weeks 10 and 20, along with glucose tolerance tests before and after intervention. Results showed increased GABA levels in all brain regions, increased NAAG levels in the frontal cortex, and decreased MI levels in the posterior cingulate after 20 weeks of GHRH administration, suggesting a potential mechanism for the favorable effects on cognition observed in adults with MCI and older adults.

This evidence supports the effectiveness of GHRH analogues like tesamorelin in enhancing cognition in early stages of dementia, suggesting a potential avenue for treatment. The findings highlight the modulation of inhibitory neurotransmitter and brain metabolite levels as a mechanism underlying the cognitive benefits observed with GHRH administration. These results not only offer promise for the treatment of dementia but also suggest new directions for research in the quest for a cure or preventative measures against cognitive decline.

[8]

All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Retatrutide · 20 mg

Description of GLP-3

GLP-3 is a synthetic peptide that acts as a triple agonist of the GCG-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and GCG receptors. This combinatorial receptor signaling enables simultaneous modulation of multiple metabolic pathways. In contrast to earlier GLP-1 receptor agonists, which primarily target appetite suppression and glycemic improvement, GLP-3 leverages GCG receptor activation to stimulate lipolysis and elevate basal metabolic rate, thereby contributing to a more pronounced and sustained reduction in adiposity as observed in research models.

The GLP-1 and GIP receptors play essential roles in augmenting insulin secretion and glucose homeostasis, whereas GCG receptor engagement elevates circulating GCG levels, promoting catabolic processes. Through this triagonist mechanism, GLP-3 has been observed in studies to reduce caloric intake and influence glycemic control while also affecting energy expenditure. This comprehensive modulation of energy balance represents a novel research strategy in the investigation of obesity, type 2 diabetes, and related metabolic disorders.

Key Research Findings

  • Triple Receptor Activation: Simultaneous stimulation of GLP-1, GIP, and Glucagon receptors for enhanced metabolic efficiency.
  • Appetite & Energy Regulation: Influences central mechanisms of appetite control and promotes caloric expenditure.
  • Glucose & Lipid Metabolism: Supports improved insulin sensitivity, glucose homeostasis, and fat oxidation.
  • Body Composition: Studied for its potential to reduce body fat while preserving lean mass.

Why Choose Retatrutide?

  • Retatrutide is one of the most advanced multi-agonist peptides currently under investigation.
  • Through its synergistic activation of GLP-1, GIP, and Glucagon receptors, it provides unique insights into the hormonal regulation of energy balance, fat metabolism, and appetite control.

Order Retatrutide and explore its potential in the next generation of metabolic and weight management research.

[1]

Overview of Published Research:

GLP-3 represents a novel generation of research compounds in the anti-obesity and antidiabetic field, characterized by its unique mechanism of action involving the simultaneous activation of three metabolically relevant receptors: the GCG-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the GCG receptor (GCGR). This triple agonism allows for an integrated modulation of key pathways regulating body weight and metabolic homeostasis. GLP-1 and GIP are incretin hormones that have been shown to influence insulin secretion, appetite, and glycemic control, while GCG primarily stimulates lipolysis, increases energy expenditure, and promotes fatty acid oxidation. As a synthetic peptide with an extended half-life, GLP-3 consolidates these effects into a once-weekly injectable formulation studied in clinical trials.

The activity of GLP-3 has been evaluated in several randomized phase 2 clinical trials, demonstrating significant weight reduction. After 48 weeks of treatment, participants receiving 8 mg and 12 mg doses experienced a mean body weight reduction of 22.8% and 24.2%, respectively—an outcome comparable to bariatric surgery. Additional observations included decreases in body mass index (BMI), waist circumference, fasting plasma glucose, HbA1c, and blood pressure. These effects were dose-dependent and particularly pronounced at higher doses. Notably, GLP-3 also exerted a substantial impact on hepatic steatosis, with liver fat volume reduced by up to 82.4% at 12 mg after 24 weeks. A considerable proportion of participants achieved a liver fat content below the threshold for steatosis (<5%), indicating research promise for metabolic liver diseases such as nonalcoholic steatohepatitis (NASH).

Given the high global prevalence of obesity and its strong association with type 2 diabetes and other chronic diseases, GLP-3 emerges as a highly promising research candidate. Ongoing phase 3 trials aim to further establish its long-term safety profile and observed activity. If positive, GLP-3 may be positioned as one of the most significant research innovations in the obesity field in recent decades.

[2] - [5]

Recent phase 2 clinical trial data evaluating the activity and safety of GLP-3 in subjects with type 2 diabetes demonstrate its pronounced effects on both glycemic control and body weight reduction. In one of the studies, patients with a mean baseline body mass index (BMI) of 35.3 kg/m² and an average HbA1c of 8.3% were randomized to receive varying doses of GLP-3 (ranging from 1 mg to 12 mg) or placebo over a 36-week study period. GLP-3 exhibited a clear dose-dependent reduction in HbA1c, with the highest dose (12 mg) achieving a mean HbA1c reduction of 2.16 percentage points from baseline, compared to only 0.43% in the placebo group—an effect that was statistically highly significant.

In addition to glycemic changes, a substantial reduction in body weight was also observed. Participants receiving the 12 mg dose of GLP-3 experienced a weight loss of up to 16.94%, corresponding to approximately 17.5 kg, while the placebo group showed a reduction of only 3.29%. The weight loss was consistent throughout the study period and showed a continued downward trend beyond week 36, suggesting a potential for sustained long-term activity. These findings highlight the dual observations with GLP-3 in subjects with type 2 diabetes, combining pronounced glucose-lowering effects with notable anti-obesity properties—particularly relevant given the strong association between obesity, insulin resistance, and impaired glycemic control.

GLP-3, as a triple agonist targeting GLP-1, GIP, and GCG receptors, holds significant promise as a research compound in the investigation of type 2 diabetes—not only through its observed influence on glycemic parameters but also via its substantial impact on weight reduction. Its activity in diabetic study populations approaches outcomes observed in individuals with obesity without diabetes, indicating its potential as a next-generation subject of investigation. These results may inform further research into more individualized approaches in subjects with diabetes and metabolic syndrome, especially in those with significant overweight or obesity.

[6], [7]

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent chronic liver disorder worldwide, with an increasing incidence driven by the global rise in obesity and metabolic syndrome. Pathophysiologically, MASLD is strongly associated with insulin resistance, leading to hepatic lipid accumulation, inflammation, and in advanced stages, fibrosis and cirrhosis.

GLP-3, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD. In a phase 2 substudy that included participants with hepatic fat content ≥10%, 48-week administration of GLP-3 resulted in a robust, dose-dependent reduction in liver fat. At doses of 8 mg and 12 mg, participants achieved a mean relative reduction in hepatic fat content of 81.4% and 82.4%, respectively, at week 24 (versus +0.3% in the placebo group), with normalization of liver fat content (<5%) observed in 79% and 86% of participants. These effects were sustained at week 48, with 89% and 93% of participants maintaining hepatic fat levels below the steatosis threshold. Additionally, liver volume decreased significantly, and improvements were observed in biomarkers of hepatic injury and inflammation, suggesting potential antifibrotic and anti-inflammatory properties in these models.

The hepatic effects of GLP-3 are likely mediated by multiple mechanisms. Most prominently, the substantial reduction in total and visceral adiposity is tightly linked to improved insulin sensitivity—a core pathophysiological determinant of MASLD. Enhanced insulin action decreases the influx of free fatty acids to the liver and suppresses hepatic de novo lipogenesis. Moreover, administration of GLP-3 resulted in favorable changes in metabolic parameters including glycemia, lipid profile, and inflammatory markers. Given the current lack of approved research compounds for metabolic dysfunction-associated steatohepatitis (MASH)—the progressive form of MASLD characterized by hepatocellular injury and fibrosis—GLP-3 emerges as a highly promising research candidate. Its multifaceted mechanism of action, encompassing weight reduction, metabolic normalization, and marked hepatic fat clearance, underscores its potential role in the further investigation of metabolic liver diseases.

[4]

All presented information is based on scientific publications which can be found in
Bacteriostatic Water · 10 ml

Bacteriostatic Water (BW) is a sterile, pyrogen-free solution used as a solvent for the reconstitution of lyophilized research peptides and laboratory compounds.

It contains 0.9% benzyl alcohol, which acts as a bacteriostatic preservative that inhibits bacterial growth, allowing the solution to remain stable under sterile conditions for multiple withdrawals.

Key Features

  • Sterile & Pyrogen-Free: Safe for laboratory use in peptide reconstitution.
  • With Benzyl Alcohol: Inhibits bacterial growth for extended usability after opening.
  • Compatibility: Suitable for all common lyophilized peptides and lab compounds.
All presented information is based on scientific publications which can be found in

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Bacteriostatic Water

Product is designed as diluent for reconstitution of lyophilised peptides. The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Use for research and scientific purposes only. Do not use for diagnostic or therapeutic purposes or as medical device.

Storage

Should be stored at room temperature and protected from direct light, excessive heat and freezing.

Reports for the included vial strengths

Tests

Tesamorelin · 20 mg

On request

Documentation is available on request

Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.

Your batch is confirmed when your order is allocated.
See all test results

Retatrutide · 20 mg

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 20mg

99.4%Purity by HPLC

Batch number
5830628
Tested
2026-07-27

Recorded QC panel

AssayPeptide screening
18.87 mg
PurityPeptide screening
99.4%
Identity (FTIR)FTIR spectrum
994
Identity (RT)Retention time
0.996
Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
0.015 EU/mg
Molecular Ion MassMS deconvolution
4731 Da

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Bacteriostatic Water · 10 ml

On request

Documentation is available on request

Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.

Your batch is confirmed when your order is allocated.
See all test results

Research sources

References

Research references concern individual compounds and experimental models. They do not establish combined efficacy of these packaged selections.

Tesamorelin · 20 mg

1.

„LiverTox: Clinical and Research Information on Drug-Induced Liver Injury“, 2018 [Internet].

2.

Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.

3.

A. Mangili, J. Falutz, J.-C. Mamputu, M. Stepanians, and B. Hayward, “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat,” PloS One, vol. 10, no. 10, p. e0140358, 2015. [PubMed]

4.

J. Falutz et al., “Metabolic effects of a growth hormone-releasing factor in patients with HIV,” N. Engl. J. Med., vol. 357, no. 23, pp. 2359–2370, Dec. 2007. [NEJM]

5.

T. L. Stanley et al., “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 54, no. 11, pp. 1642–1651, Jun. 2012. [PubMed]

6.

V. Rochira and G. Guaraldi, “Growth hormone deficiency and human immunodeficiency virus,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91–111, 2017. [PubMed]

7.

S. H. Tuffaha et al., “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury,” Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259–1265, Oct. 2016. [PubMed]

8.

S. D. Friedman et al., “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging,” JAMA Neurol., vol. 70, no. 7, pp. 883–890, Jul. 2013. [PubMed]

9.

National Center for Biotechnology Information

PubChem Compound Summary: Tesamorelin

Authoritative identity record for the compound sold under the Tesa catalogue name.

PubChem View source ↗
10.

Chemical Abstracts Service

CAS Common Chemistry: 218949-48-5

Authoritative CAS Registry Number record for Tesamorelin.

CAS Common Chemistry View source ↗
11.

Russo SC, Ockene MW, Arpante AK, et al. · 2024

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Primary clinical research report for the compound described as Tesamorelin.

AIDS · 10.1097/qad.0000000000003965 View source ↗
12.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · 2010

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

The Journal of clinical endocrinology and metabolism View source ↗
13.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK · 2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

The lancet. HIV View source ↗
14.

Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV · 2012

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

Archives of neurology View source ↗
15.

Lauritzen L, Amundsen ID, Damsgaard CT, Lind MV, Schnurr TM, Hansen T, Michaelsen KF, Vogel U · 2019

FADS and PPARG2 Single Nucleotide Polymorphisms are Associated with Plasma Lipids in 9-Mo-Old Infants

The Journal of nutrition View source ↗
16.

Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK · 2020

PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma

JCI insight View source ↗

Retatrutide · 20 mg

1.

„Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment", 2025.

2.

Alaa Abdrabou Abouelmagd et al., „Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials", 2025.

3.

Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013. [DOI] [PubMed]

4.

Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

5.

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972. [DOI] [PubMed]

6.

Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]

7.

Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]

8.

Coskun T, Urva S, Roell WC, et al. · 2022

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Discovery, molecular design, and receptor characterisation of LY3437943.

Cell Metabolism · 10.1016/j.cmet.2022.07.013 View source ↗
9.

Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Clinical research report concerning the compound described as retatrutide.

The New England Journal of Medicine · 10.1056/nejmoa2301972 View source ↗
10.

National Center for Biotechnology Information

PubChem Compound Summary: Retatrutide

Authoritative identity record for retatrutide, also described as LY3437943.

PubChem View source ↗
11.

Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D · 2025

Triple Agonism Based Therapies for Obesity

Current cardiovascular risk reports View source ↗
12.

Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K · 2025

Retatrutide-A Game Changer in Obesity Pharmacotherapy

Biomolecules View source ↗
13.

Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM · 2025

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

Proceedings (Baylor University. Medical Center) View source ↗
14.

· 2025

Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment

2025
15.

Alaa Abdrabou Abouelmagd et al. · 2025

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

2025
16.

· 2024

Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

· 10.1038/s41591-024-03018-2 View source ↗
17.

· 2023

Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]

· 10.1016/s0140-6736(23)01053-x View source ↗
18.

· 2022

Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]

· 10.1016/s0140-6736(22)02033-5 View source ↗

Bacteriostatic Water · 10 ml

1.

National Center for Biotechnology Information

PubChem Compound Summary: Benzyl alcohol

Authoritative identity record for the preservative component of Bacteriostatic Water.

PubChem View source ↗
2.

Chemical Abstracts Service

CAS Common Chemistry: 7732-18-5

Authoritative CAS Registry Number record for water.

CAS Common Chemistry View source ↗
3.

Chemical Abstracts Service

CAS Common Chemistry: 100-51-6

Authoritative CAS Registry Number record for benzyl alcohol.

CAS Common Chemistry View source ↗

Signed certificate

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →